A Basket Trial of Pembrolizumab in Patients with Advanced Solid Tumors and Genomic Instability

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Advanced Solid Tumors And Genomic Instability
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Have a diagnosis of a tumor with evidence of genomic instability or DNA repair deficiency on CLIA certified genomic testing. 2) Have advanced cancer (metastatic, recurrent or locally advanced) and measurable disease based on RECIST 1.1. 3) Be willing to provide archived tumor tissue. 4) Demonstrate adequate organ function.

You may not be eligible for this study if the following are true:

  • 1) Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment. 2) Has a diagnosis of immunodeficiency that consistently requires more than 10 mg daily of prednisone or equivalent or has resulted in life threatening episodes previously regardless of current treatment. 3) Has a known history of active TB (Bacillus Tuberculosis).

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.